<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11204">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593333</url>
  </required_header>
  <id_info>
    <org_study_id>F030211012</org_study_id>
    <nct_id>NCT00593333</nct_id>
  </id_info>
  <brief_title>Intramedullary Nailing of the Femur:Trochanteric vs Piriformis Starting Portals</brief_title>
  <acronym>TROCHNAIL</acronym>
  <official_title>Intramedullary Nailing of the Femur: A Comparison of the Trochanteric and Piriformis Starting Portals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Smith &amp; Nephew, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is designed to determine whether or not the trochanteric insertion portal will
      show any difference when compared with the piriformis fossa portal in terms of pain and
      strength of the hip abductor muscles, while allowing faster surgical fixation of the femur
      fracture.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is designed as a prospective, randomized, comparative study between the Trigen
      Trochanteric Femoral Nail (Smith &amp; Nephew, Memphis) and a standard femoral intramedullary
      nail that utilizes a piriformis fossa portal in the treatment of fractures of the
      subtrochanteric and diaphyseal shaft regions of the femur. The hypothesis is that the
      trochanteric insertion portal will have no difference when compared with the piriformis
      fossa portal in terms of pain and strength of the hip abductor muscles, while allowing
      faster surgical fixation of the femur fracture.

      Any patient who has sustained a fracture of the femur, is at least 19 years of age, and
      meets the study's inclusion and exclusion criteria will be asked to participate in the
      study. After informed consent has been obtained, the patient will be taken to the Operating
      Theater for surgical fixation of the femur fracture. No fracture will be entered into the
      study unless antegrade femoral nailing is the treatment of choice of the attending surgeon.

      The outcome variables consist of the intraoperative and postoperative adverse device effects
      recorded in the medical record and on the study data collection form, intraoperative and
      postoperative complications recorded in medical record and on the study data collection
      form, hip functional outcome using the WOMAC score recorded for each patient, SF-36 score
      recorded for each patient, results of clinical examination at 6 weeks, 3, 6, and 12 months
      recorded in medical record and on the study data collection form, radiographic examination
      evaluated by two surgeons for the presence of callus and radiographic healing recorded in
      the medical record and on the study data collection form. Radiographic healing at 6 weeks,
      3, 6, and 12 months recorded in the medical record and on the study data collection form.
      (The injury severity score for all multiple trauma patients recorded on the study data
      collection form, and soft tissue score according to Gustillo and Anderson for open injuries
      and according to Tscherne for all closed injuries recorded on the study data collection
      form. This data will be taken into account relative to the outcome variables). The effects
      will be measured by clinical examination, radiographic examination, and subjective patient's
      outcome survey. Additionally, hip abductor muscle strength will be measured and ability to
      perform one leg stance and hop will be documented at 6 and 12 months.

      Data will be collected and entered into EXCEL spreadsheets with double keying for quality
      control purposes and managed by the Department of Orthopaedic Surgery at the University of
      Alabama at Birmingham (UAB). After data entry is complete, the file(s) will be copied to
      diskette and delivered to the UAB Biostatistics statistician for analysis and report
      generation. The analysis will involve simple descriptive statistics (means, standard
      deviations, proportions) to assure balance of the treatment groups with respect to relevant
      variables. T-test will be used to compare the mean times to callus formation and
      radiographic healing between groups. Analysis of covariance will be performed if there are
      variables that require adjustment. Growth curve analysis (survival models) and Cox
      regression procedures will be used to compare the rates of callus formation and/or healing
      between the two groups. Assumption of proportional hazards in the model will be verified
      before attempting Cox regression procedures. P-values will be computed using a Mann-Whitney
      U test for non-parametric data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Healed Femur Fracture</measure>
    <time_frame>baseline to healed fracture (weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to clinically healed fracture as measured by weeks.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Femur Fracture</condition>
  <arm_group>
    <arm_group_label>1, A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard femoral intramedullary nail that utilizes a piriformis fossa portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2, B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trigen Trochanteric Femoral Nail (Smith &amp; Nephew, Memphis)using a trochanteric insertion portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Antegrade Intramedullary Nail</intervention_name>
    <description>Use of an antegrade intramedullary nail implanted through the Piriformis fossa of the femur. The use of these nails has yielded a union rate of 97 - 99%, and has clearly become the most commonly utilized implant for femur fractures.</description>
    <arm_group_label>1, A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trigen Trochanteric Femoral Nail</intervention_name>
    <description>Antegrade intramedullary nails developed with a proximal lateral bend that allows implantation through the greater trochanter rather than the piriformis fossa. This start portal is remarkably easier to locate and may be associated with decreased risk of abductor muscle weakness and pain.</description>
    <arm_group_label>2, B</arm_group_label>
    <other_name>Trigen Trochanteric Femoral Nail, Smith &amp; Nephew, Inc.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fracture patterns of the proximal or middle thirds of the femur that will allow
             antegrade insertion of a femoral nail

          -  Adult patient (19 years and older)

        Exclusion Criteria:

          -  Nonunions of the femur

          -  Pathologic fractures

          -  Documented prior femur fractures with surgical stabilization with an antegrade nail

          -  Patients who are pregnant, mentally disturbed, or prisoners

          -  Inability to comply with protocol

          -  Patients or family members who are unable or unwilling to sign study consent

          -  Any fracture too proximal or too distal to use an interlocking screw
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Volgas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham, Orthopaedic Trauma</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ricci WM, Schwappach J, Tucker M, Coupe K, Brandt A, Sanders R, Leighton R. Trochanteric versus piriformis entry portal for the treatment of femoral shaft fractures. J Orthop Trauma. 2006 Nov-Dec;20(10):663-7.</citation>
    <PMID>17106375</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>September 5, 2013</lastchanged_date>
  <firstreceived_date>December 20, 2007</firstreceived_date>
  <firstreceived_results_date>September 5, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Femur Fracture</keyword>
  <keyword>Intramedullary Nailing</keyword>
  <keyword>Trochanteric Nailing</keyword>
  <keyword>Piriformis Starting Portal</keyword>
  <keyword>Trochanteric Insertion Portal</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Femoral Fractures</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>Piriformis fossa entry portal for the antegrade nailing was used for this group. Received either a TRIGEN antegrade femoral nail manufactured by Smith &amp; Nephew (Memphis, Tennessee) or an Antegrade Femoral Nail manufactured by Synthes (West Chester, Pennsylvania)</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>Trochanteric entry portal for the antegrade nailing was used for this group. These subjects received a TRigen Trochanteric Angegrade Nail (TAN) manufactured by Smith &amp; Nephew that incorporates a 4 degree valgus bend in the proximal aspect of the nail.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Treatment</title>
        </group>
        <group group_id="B2">
          <title>Trigen</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="54"/>
                <measurement group_id="B2" value="56"/>
                <measurement group_id="B3" value="110"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="53"/>
                <measurement group_id="B2" value="54"/>
                <measurement group_id="B3" value="107"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="27"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
                <measurement group_id="B2" value="40"/>
                <measurement group_id="B3" value="83"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="68"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hispanic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="54"/>
                <measurement group_id="B2" value="56"/>
                <measurement group_id="B3" value="110"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Healed Femur Fracture</title>
        <description>Time to clinically healed fracture as measured by weeks.</description>
        <time_frame>baseline to healed fracture (weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Piriformis fossa entry portal for the antegrade nailing was used for this group. Received either a TRIGEN antegrade femoral nail manufactured by Smith &amp; Nephew (Memphis, Tennessee) or an Antegrade Femoral Nail manufactured by Synthes (West Chester, Pennsylvania)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Trochanteric entry portal for the antegrade nailing was used for this group. These subjects received a TRigen Trochanteric Angegrade Nail (TAN) manufactured by Smith &amp; Nephew that incorporates a 4 degree valgus bend in the proximal aspect of the nail.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Healed Femur Fracture</title>
            <description>Time to clinically healed fracture as measured by weeks.</description>
            <units>use weeks</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31.8" lower_limit="10.3" upper_limit="64.3"/>
                  <measurement group_id="O2" value="31.4" lower_limit="6.3" upper_limit="108.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were followed through 12 months after intervention</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>Piriformis fossa entry portal for the antegrade nailing was used for this group. Received either a TRIGEN antegrade femoral nail manufactured by Smith &amp; Nephew (Memphis, Tennessee) or an Antegrade Femoral Nail manufactured by Synthes (West Chester, Pennsylvania)</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Trochanteric entry portal for the antegrade nailing was used for this group. These subjects received a TRigen Trochanteric Angegrade Nail (TAN) manufactured by Smith &amp; Nephew that incorporates a 4 degree valgus bend in the proximal aspect of the nail.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>other</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hematoma requiring surgical intervention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Implant failure requiring revision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>other</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Implant failure not requiring surgical intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Healed with malalignment</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Taylor Vlack, Research Nurse Coordinator</name_or_title>
      <organization>Department of Surgery/Division of Orthopaedics</organization>
      <phone>205-996-6781</phone>
      <email>tmwebb@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
